The Lira Pump Trial

Sponsor
Hvidovre University Hospital
Study ID
NCT02351232
Phase
PHASE2/PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

A randomized placebo-controlled clinical trial investigating the effects of Liraglutide as an add-on to intensive insulin therapy in overweight insulin pump treated type 1 diabetes patients in suboptimal glycemic control.

Key Dates

Start date
Feb 28, 2015
Status verified
Oct 2016
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016

Study Design

Enrollment
44 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention
    Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months
  • Placebo Comparator: Placebo
    Placebo; daily subcutaneous injection; 1.8 mg; 6 months

Primary Outcome Measure

Change in HbA1c [ Time Frame: 6 months ]

Related Studies